自身免疫性肝炎

Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193-2213.

• 全文
• 摘要

Gleeson D, Heneghan MA; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611-1629.

• 全文
• 摘要

Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis. 2009;29:273-285.

• 摘要

Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012;36:691-707.

• 全文
• 摘要

Czaja AJ. Current and prospective pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother. 2014;15:1715-1736.

• 摘要

1.  Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193-2213.

• 全文
• 摘要

2.  Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis. 2004;1:2.

• 全文
• 摘要

3.  Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354:54-66.

• 摘要

4.  Boberg KM. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis. 2002;6:635-647.

• 摘要

5.  Czaja AJ. Autoimmune hepatitis: approach to diagnosis. MedGenMed. 2006;8:55.

• 摘要

6.  Czaja AJ, Freese DK. American Association for the Study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479-497.

• 全文
• 摘要

7.  Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol. 2006;22:234-240.

• 摘要

8.  Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology. 2006;43:S132-S144.

• 摘要

9.  Doherty DG, Donaldson PT, Underhill JA, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology. 1994;19:609-615.

• 摘要

10.  Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol. 2005;21:293-299.

• 摘要

11.  Czaja AJ. Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis. 1984;4:1-12.

• 摘要

12.  Czaja AJ, Cassani F, Cataleta M, et al. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology. 1996;24:1068-1073.

13.  Maharaj B, Bhoora IG. Complications associated with percutaneous needle biopsy of the liver when one, two or three specimens are taken. Postgrad Med J. 1992;68:964-967.

14.  Tonolini M, Bianco R. HIV-related/AIDS cholangiopathy: pictorial review with emphasis on MRCP findings and differential diagnosis. Clin Imaging. 2013;37:219-226.

• 摘要

15.  Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938.

• 摘要

16.  Gleeson D, Heneghan MA; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611-1629.

• 全文
• 摘要

17.  Lamers MM, van Oijen MG, Pronk M, et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010;53:191-198.

• 全文
• 摘要

18.  Yeoman AD, Longhi MS, Heneghan MA. Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther. 2010;31:771-787.

• 全文
• 摘要

19.  Zandieh I, Krygier D, Wong V, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol. 2008;22:388-392.

• 全文
• 摘要

20.  Wiegand J, Schüler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005;25:927-934.

• 摘要

21.  Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis. 2009;29:273-285.

• 摘要

22.  Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198-1206.

• 摘要

23.  Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther. 1994;8:585-590.

• 摘要

24.  Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology. 2000;119:1312-1316.

• 摘要

25.  Csepregi A, Röcken C, Treiber G, et al. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol. 2006;12:1362-1366.

• 摘要

26.  Woynarowski M, Nemeth A, Baruch Y, et al; European Autoimmune Hepatitis-Budesonide Study Group. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr. 2013;163:1347-1353.

• 摘要

27.  Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012;36:691-707.

• 全文
• 摘要

28.  Strassburg CP, Bahr MJ, Becker T, et al. Progress in immunosuppression. Chirurg. 2008;79:149-156. [In German]

• 摘要

29.  Nasseri-Moghaddam S, Nikfam S, Karimian S, et al. Cyclosporine-A versus prednisolone for induction of remission in auto-immune hepatitis: interim analysis report of a randomized controlled trial. Middle East J Dig Dis. 2013;5:193-200.

• 全文
• 摘要

30.  Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001;46:1321-1327.

• 摘要

31.  Czaja AJ. Current and prospective pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother. 2014;15:1715-1736.

• 摘要

32.  Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis. 2009;29:286-96.

• 摘要

33.  Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl. 2002;8:519-526.

• 全文
• 摘要

34.  Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124:9-17.

• 全文
• 摘要

35.  European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971-1004.

• 全文
• 摘要

36.  Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013;58:529-534.

• 摘要

37.  Rebollo Bernárdez J, Cifuentes Mimoso C, Piñar Moreno A, et al. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis. Rev Esp Enferm Dig. 1999;91:630-638.

• 摘要

38.  Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:771-776.

• 摘要

39.  Kanzler S, Gerken G, Dienes HP, et al. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis: report of three cases. Z Gastroenterol. 1997;35:571-578.

• 摘要

40.  Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology. 1999;30:1381-1386.

• 摘要

41.  Miyake Y, Iwasaki Y, Kobashi H, et al. Efficacy of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. Hepatol Int. 2009;3:556-562.

• 摘要

42.  Squires RH, Ng V, Romero R, et al. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Hepatology. 2014;60:362-398.

• 全文
• 摘要

43.  Kirk AP, Jain S, Pocock S, et al. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut. 1980;21:78-83.

• 全文
• 摘要

44.  Montano-Loza AJ, Mason AL, Ma M, et al. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15:1254-1561.

• 摘要

45.  Andries S, Casamayou L, Sempoux C, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation. 2001;72:267-272.

• 摘要

46.  Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis. 2009;29:315-330.

• 摘要

47.  Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43:532-538.

• 全文
• 摘要

48.  Miyake T, Miyaoka H, Abe M, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res. 2006;36:139-142.

• 摘要

49.  Cross TJ, Antoniades CG, Muiesan P, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl. 2007;13:1382-1388.

• 全文
• 摘要

50.  Candia L, Marquez J, Espinoza LR. Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Semin Arthritis Rheum. 2005;35:49-56.

• 摘要

51.  Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7:319-333.

• 摘要

52.  Viruet EJ, Torres EA. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J. 1998;17:297-300.

• 摘要

53.  Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95:448-453.

• 摘要

54.  Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46:1138-1145.

• 摘要